Quantcast

Latest Antipsychotic Stories

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-04 23:28:40

Gordon & Doner is extending free consultations to patients who allegedly suffered serious health consequences after being prescribed the antipsychotic medication Risperdal WEST PALM BEACH, Fla (PRWEB) March 04, 2014 With litigation pending in the Court of Common Pleas, Philadelphia County, Pennsylvania (case no. 100300296,) South Florida law firm Gordon & Doner is now accepting injury claims and inquiries about the dangers of the antipsychotic medication, Risperdal. “Our goal is...

2014-03-04 23:25:04

The global market for drugs used to treat mental disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018. Wellesley, Mass., (PRWEB) March 04, 2014 According to a new technical market research report Drugs for Treating Mental Disorders: Technologies and Global Markets, from...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-03-03 08:30:51

NEW YORK, March 3, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease....

High Dose Antidepressant Offers Some Hope For Alzheimer's Patients
2014-02-19 12:58:56

Brett Smith for redOrbit.com - Your Universe Online Agitation is a common symptom in patients with Alzheimer's disease and is associated with severe adverse consequences for both patients and caregivers. According to a new study published in JAMA, a high dose of the antidepressant citalopram considerably reduced agitation in patients with Alzheimer’s. However, the drug administered at this dose was also associated with mild adverse cognitive and cardiac effects – a sign that this...

2014-02-12 12:32:22

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- As Risperdal gynecomastia lawsuits (http://www.risperdallawsuitcenter.com/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the state of Ohio has launched an initiative to curb the overuse of antipsychotic drugs like Risperdal in children. The initiative is part of Ohio Minds Matter, an effort by the state to evaluate and improve prescribing of atypical antipsychotics and other psychotropic medications among...

2014-02-12 08:28:44

-- Eisai's Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena -- SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). In connection with the filing, Arena will receive a...

2014-02-11 16:25:38

First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. "We are pleased to offer patients with...

2014-02-10 08:26:31

-- BELVIQ Now Covered by CVS Caremark -- SAN DIEGO, Calif., Feb. 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai has secured improved patient access of BELVIQ(®) (lorcaserin HCl) with two leading healthcare benefit companies, and that the estimated number of insured commercial lives in the United States that have coverage for BELVIQ now exceeds 50 percent. CVS Caremark customers (employers and health plans) have broadened the coverage of...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.